News | Heart Valve Technology | June 21, 2024

Novel Tricuspid Valve Procedure Improves Patients' Quality of Life and Health Status

UCSF surgeons among the first in nation to conduct minimally invasive cardiac procedure to improve patients’ quality of life

UCSF surgeons among the first in nation to conduct minimally invasive cardiac procedure to improve patients’ quality of life

June 21, 2024 — UC San Francisco interventional cardiologists and interventional echocardiographers recently performed the health system’s first commercial transcatheter tricuspid valve replacement procedure using the Edwards EVOQUE system. The novel and minimally invasive cardiac procedure was recently approved for use within the U.S. by the Food and Drug Administration. The UCSF team is the first to perform the commercial procedure across the UC system and in San Francisco and is one of only a handful of centers currently performing the procedure nationally.

The EVOQUE tricuspid valve replacement system is a device designed to treat patients with severe leaking of the tricuspid valve, known as tricuspid regurgitation, without open heart surgery. The EVOQUE valve is implanted using a minimally invasive delivery system (a catheter) through the femoral vein reaching to the heart.

“Patients suffering with debilitating symptoms as a result of tricuspid regurgitation represent a large and significantly underserved patient group,” said Sammy Elmariah, MD, UCSF chief of Interventional Cardiology. “The EVOQUE tricuspid valve replacement system represents a major advance for a group of patients who previously had limited treatment options.”

Tricuspid regurgitation occurs when the tricuspid valve in the heart does not close completely, usually because the valve or surrounding structures have dilated or stretched, preventing the valve leaflets from closing tightly. Blood then flows backwards within the heart and may cause symptoms such as shortness of breath and swelling in the abdomen, legs or veins in the neck. 

UCSF’s multidisciplinary heart valve team began performing the tricuspid valve replacement procedure using the Edwards Lifesciences EVOQUE system in 2023, as part of the TRISCEND II clinical trial evaluating the safety and effectiveness of the EVOQUE system. 

“The recent FDA approval of the EVOQUE tricuspid valve replacement system is a monumental step forward in transcatheter options for the oft forgotten tricuspid valve,” said Neal Shah, MD,  a UCSF cardiologist who specializes in cardiac imaging. “With a clear percutaneous option now available, we can provide advanced treatments to patients who would otherwise not receive definitive care for their leaky valve.” 

In addition to minimally invasive tricuspid valve replacement, Elmariah and the interventional cardiology team are also investigating how to increase access to other heart valve disease treatments and improve patient involvement in the management of their own care.

For more information: https://ucsfhealth.org

 

Related Content:

Edwards Evoque Transcatheter Tricuspid Valve Replacement System Receives CE Mark

Edwards Announces One-year Data on Transfemoral Transcatheter Tricuspid Valve Replacement 

Six-Month Outcomes Positive for Transfemoral Tricuspid Valve in Tricuspid Regurgitation Patients 

Edwards LifeSciences Reports Positive Clinical Updates on its Transcatheter Mitral and Tricuspid Valves 


Related Content

News | Heart Valve Technology

June 27, 2024 — The sheer scale of undiagnosed heart valve disease in our aging population has been revealed for the ...

Home June 27, 2024
Home
News | Heart Valve Technology

June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial ...

Home June 10, 2024
Home
News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
News | Heart Valve Technology

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
News | Heart Valve Technology

January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart ...

Home January 04, 2024
Home
News | Heart Valve Technology

December 22, 2023 — TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of ...

Home December 22, 2023
Home
News | Heart Valve Technology

December 18, 2023 — Death rates related to infective endocarditis declined in most adults across the U.S. within the ...

Home December 18, 2023
Home
News | Heart Valve Technology

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

Home December 12, 2023
Home
News | Heart Valve Technology

November 20, 2023 — Abbott announced new late-breaking data that show advanced heart failure patients living with its ...

Home November 20, 2023
Home
News | Heart Valve Technology

October 24, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announced that novel data from seven research studies ...

Home October 24, 2023
Home
Subscribe Now